Nyxoah Set to Release Fourth Quarter and Year-End Financial Results
Nyxoah SA (NASDAQ: NYXH), a medical technology company dedicated to innovating treatment options for Obstructive Sleep Apnea (OSA), is gearing up to release its financial results for the fourth quarter and the complete financial year 2024. Scheduled for March 13, 2025, this announcement marks an important occasion for stakeholders eager to learn about the company's performance and future directions.
Details of the Earnings Release
The company's management team will be hosting a comprehensive conference call that day at 1:00 PM CET / 8:00 AM ET. During this session, they will discuss the financial results and share valuable insights into the company’s strategic initiatives moving forward. This event is especially significant as it showcases the company’s efforts and advancements in combating OSA.
Investors Can Access Webcast and Q&A
For those interested in tuning in, a webcast will be available via Nyxoah’s Investor Relations page. The company encourages participants who wish to pose questions to sign up through the provided link. An email will be sent to them shortly thereafter, including dial-in details and a unique access code necessary for joining the call. It’s recommended that those planning to participate register at least 10 minutes in advance to ensure a smooth connection.
About Nyxoah's Innovative Solutions
Nyxoah has made significant strides in the medical technology sector by developing groundbreaking treatment alternatives for OSA. Their flagship product, Genio®, is a battery-free hypoglossal neuromodulation device that is designed for ease of use by being inserted through a single incision under the chin. This innovative device stands out for its user-friendliness, being controlled with a wearable device, changing the way patients experience treatment.
Company Milestones and Growth
Nyxoah has achieved notable milestones throughout its journey. In 2019, after the successful completion of the BLAST OSA study, the Genio® system received the CE mark in Europe, paving the way for its clinical use. The company carried out two successful Initial Public Offerings - first on Euronext Brussels in September 2020 and then on NASDAQ in July 2021. The Genio® system also received expanded therapeutic indication approvals, enhancing treatment options for patients experiencing Complete Concentric Collapse, a condition that other therapies are unable to address.
Future Directions and Clinical Outcomes
Following positive results from the BETTER SLEEP study, Nyxoah announced its plans to apply for further regulatory approvals. Positive outcomes from pivotal studies have paved the way for potential commercialization in the U.S., emphasizing the company’s commitment to expanding its reach and capabilities in fight against OSA. Nyxoah aims to enhance the quality of life for the millions affected by sleep apnea globally through clinical innovations.
Frequently Asked Questions
When will Nyxoah release its fourth quarter financial results?
Nyxoah will release its fourth quarter financial results on March 13, 2025.
How can I participate in Nyxoah's conference call?
You can participate by registering for the conference call via the Investor Relations page on Nyxoah's website.
What innovative products does Nyxoah offer?
Nyxoah offers the Genio®, a hypoglossal neuromodulation device designed specifically for patients suffering from obstructive sleep apnea.
What are Nyxoah's recent achievements?
Nyxoah received its European CE Mark in 2019 and successfully completed IPOs on Euronext and NASDAQ, showcasing its growth in the medical technology sector.
What are the future plans for Nyxoah?
Nyxoah plans to pursue additional regulatory approvals in the U.S. to expand the commercialization of its innovative therapies.
